- May 23, 2021Annovis Bio, Inc. Announces Pricing of Public Offering
- May 21, 2021Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
- May 21, 2021Annovis Bio Announces Positive Phase 2 Data – ANVS401 Improves Cognition in Alzheimer’s Disease - Patients’ Cognition Improved 3.3 Points on ADAS-Cog11
- October 01, 2019Axonal Transport and Neurological Disease
- May 21, 2019How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?
- April 30, 2019After amyloid failures, it’s time to take a new tack for treating Alzheimer’s
Back to Top